MX9704560A - Receptor novedoso. - Google Patents

Receptor novedoso.

Info

Publication number
MX9704560A
MX9704560A MX9704560A MX9704560A MX9704560A MX 9704560 A MX9704560 A MX 9704560A MX 9704560 A MX9704560 A MX 9704560A MX 9704560 A MX9704560 A MX 9704560A MX 9704560 A MX9704560 A MX 9704560A
Authority
MX
Mexico
Prior art keywords
rat forebrain
forebrain tissue
binds
compound
novel receptor
Prior art date
Application number
MX9704560A
Other languages
English (en)
Other versions
MXPA97004560A (es
Inventor
Hugh Jonathan Herdon
Jeffrey Clifford Jerman
Wai Ngor Chan
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9704560A publication Critical patent/MX9704560A/es
Publication of MXPA97004560A publication Critical patent/MXPA97004560A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un receptor en forma substancialmente pura que se obtiene a partir de tejido de prosencéfalo de rata caracterizado porque, a) el compuesto A se une a él con una Kd de 48mM para tejido de prosencéfalo de rata; b) el compuesto A se une a él con una Bmax de 220 pmol/g de proteína para tejido de prosencéfalo de rata; c) el compuesto D se une a él con una Kd de 2nM para tejido de prosencéfalo de rata; d) el compuesto B se une a él con una Bmax de 220 pmol/g de proteína para tejido de prosencéfalo de rata; y receptores homologos de otras fuentes que comparten por lo menos 85% de homología con el tejido de prosencéfalo de rata.
MXPA/A/1997/004560A 1994-12-17 1997-06-17 Receptor novedoso MXPA97004560A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9425502.3 1994-12-17
GBGB9425502.3A GB9425502D0 (en) 1994-12-17 1994-12-17 Novel receptor
PCT/EP1995/004998 WO1996018650A1 (en) 1994-12-17 1995-12-11 Novel receptor

Publications (2)

Publication Number Publication Date
MX9704560A true MX9704560A (es) 1997-10-31
MXPA97004560A MXPA97004560A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
FI972558L (fi) 1997-06-16
CN1175262A (zh) 1998-03-04
AU4345896A (en) 1996-07-03
BR9510060A (pt) 1998-06-02
WO1996018650A1 (en) 1996-06-20
GB9425502D0 (en) 1995-02-15
FI972558A0 (fi) 1997-06-16
NZ298059A (en) 2000-03-27
CA2207921A1 (en) 1996-06-20
US5985334A (en) 1999-11-16
NO972771L (no) 1997-08-15
HUT77077A (hu) 1998-03-02
NO972771D0 (no) 1997-06-16
PL320747A1 (en) 1997-10-27
JPH10511083A (ja) 1998-10-27
FI972558A7 (fi) 1997-06-16
CZ187697A3 (en) 1997-10-15
AU710150B2 (en) 1999-09-16
EP0807122A1 (en) 1997-11-19

Similar Documents

Publication Publication Date Title
Dolphin G protein modulation of voltage-gated calcium channels
BR0005995A (pt) Composição cosmética sem transferência que compreende um composto não volátil siliconado e um óleo hidrocarbonado não volátil incompatìvel com esse composto siliconado.
MY117251A (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
PT1849866E (pt) Receptor acoplado à proteína g órfão humano, rup3
AU2432002A (en) 3-substituted oxindole beta 3 agonists
ES2138977T3 (es) Agonistas muscarinicos.
BRPI0418209A (pt) solado respirável e à prova d'água para sapatos e sapato respirável e à prova d'água
EP1958965A3 (en) Agonist antibodies to a musk receptor, and their therapeutic uses
EE200100006A (et) Bifenüülsulfoonamiidid kui duaalse angiotensiin-endoteliini retseptori antagonistid
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
EP1476120A4 (en) THERAPEUTIC METHODS USING ANTI-CD22 ANTIBODIES
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
PE20091674A1 (es) Antagonistas del receptor de glucagon
BG101110A (bg) Заместени пиримидинови съединения и тяхното използване
ATE346869T1 (de) Agonistische antikörper gegen tie2
DE69734157D1 (en) Parathyroidhormon-verwandthe peptidanaloge
BG103548A (en) Vitronectine receptor antagonists
EA200001039A1 (ru) Кальцилитические соединения
TR200202326T2 (tr) Hipertrofi ile birlikte görülen miyokard rahatsızlıkların tedavisinde bradikardilerin kullanımı
MX9704560A (es) Receptor novedoso.
NO20031033D0 (no) Reseptor i EDb-fibronectindomene
NZ504471A (en) An Ox receptor distinct from known alpha 2-adenoreceptors and imidazoline receptors (I1 and I2) with an affinity for compounds of the oxazoline class
SE9702794D0 (sv) New compounds
MXPA02010241A (es) Receptor edg8, su preparacion y uso.